ArticleFrontiers in psychiatry2026
The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: modulation of the depressive burden in a longitudinal study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This longitudinal observational study evaluated changes in depressive symptoms associated with ritualistic ayahuasca use in patients diagnosed with depressive disorders, as well as depressive burden in individuals with anxiety and substance use disorders. Methods: The research was conducted with 280 adults treated at clinics in the northwestern region of the state of São Paulo, under the jurisdiction of Regional Health Division XV (DRS XV), which covers a population of over 2 million inhabitants. Participants were assessed at six different time points over a six-month follow-up period after the ayahuasca intervention, with depressive symptoms measured using the Montgomery-Åsberg Depression Rating Scale (MADRS). Results: The results indicate a significant reduction in depression scores shortly after the intervention, with improvements sustained for up to 180 days, though individual responses varied. The analysis reveals that ayahuasca, when combined with psychotherapeutic support, can provide significant benefits in reducing symptoms of depression and anxiety, and also shows potential in the treatment of substance dependence. Conclusion: We concluded that the final variability in responses suggests that psychodynamic and clinical factors, such as the integration of the psychedelic experience and therapeutic support, play a crucial role in treatment effectiveness. This study contributes to the consolidation of psychedelic-assisted therapeutic protocols, highlighting the importance of continuous and personalized follow-up in the treatment of complex psychiatric conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.